FLOXIN OTIC Drug Patent Profile

Which patents cover Floxin Otic, and what generic alternatives are available?

Floxin Otic is a drug marketed by Daiichi and is included in one NDA.

The generic ingredient in FLOXIN OTIC is ofloxacin. There are seventy-eight drug master file entries for this compound. Thirty-one suppliers are listed for this compound. Additional details are available on the ofloxacin profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Floxin Otic

A generic version of FLOXIN OTIC was approved as ofloxacin by CHARTWELL RX on September 2^nd, 2003.

Summary for FLOXIN OTIC

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	149
Clinical Trials:	8
Patent Applications:	4,084
DailyMed Link:	FLOXIN OTIC at DailyMed

Recent Clinical Trials for FLOXIN OTIC

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Montefiore Medical Center	Phase 3
University of California, San Francisco	Phase 4
Winston Chamberlain, MD, PhD	Phase 4

See all FLOXIN OTIC clinical trials

US Patents and Regulatory Information for FLOXIN OTIC

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Daiichi	FLOXIN OTIC	ofloxacin	SOLUTION/DROPS;OTIC	020799-001	Dec 16, 1997		DISCN	Yes	No

Expired US Patents for FLOXIN OTIC

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Daiichi	FLOXIN OTIC	ofloxacin	SOLUTION/DROPS;OTIC	020799-001	Dec 16, 1997

International Patents for FLOXIN OTIC

See the table below for patents covering FLOXIN OTIC around the world.

Country	Patent Number	Title	Estimated Expiration
Denmark	175302
Japan	H0334925	LOCAL PREPARATION FOR EAR DISEASE
Germany	68917186
Ireland	65859	Use of ofloxacin or a salt thereof for preparing a topical preparation for treating otopathy
South Korea	0126471
Hong Kong	196596	Use of ofloxacin or a salt thereof for preparing a topical preparation for treating otopathy
Denmark	168189

Supplementary Protection Certificates for FLOXIN OTIC

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1429780	SPC/GB12/058	United Kingdom		PRODUCT NAME: A COMBINATION OF CIPROFLOXACIN AND DEXAMETHASONE, PREFERABLY CIPROFLOXACIN HYDROCHLORIDE AND DEXAMETHASONE; REGISTERED: DK DE/11/3337/001/DC 20120808; UK PL000649/0381-0001 20121003
1429780	132013902137451	Italy		PRODUCT NAME: CIPROFLOXACINA E DESAMETASONE(CILODEX); AUTHORISATION NUMBER(S) AND DATE(S): 48976, 20120810;041182015/M, 20121106
1429780	13C0012	France		PRODUCT NAME: COMBINAISON DE CIPROFLOXACINE ET DE DEXAMETHASONE, EN PARTICULIER DE CHLORHYDRATE DE CIPROFLOXACINE ET DE DEXAMETHASONE; NAT. REGISTRATION NO/DATE: NL 41308 20121214; FIRST REGISTRATION: 48976 20120808
1429780	122012000070	Germany		PRODUCT NAME: KOMBINATION AUS CIPROFLOXACIN UND DEXAMETHASON, INSBESONDERE CIPROFLOXACINHYDROCHLORID UND DEXAMETHASON; NAT. REGISTRATION NO/DATE: 85150.00. 00 20120830; FIRST REGISTRATION: DAENEMARK 48976 20120808
0206283	98C0041	Belgium		PRODUCT NAME: LEVOFLOXACINUM HEMIHYDRICUM; NAT. REGISTRATION NO/DATE: 354 IS 370 F3 19980624; FIRST REGISTRATION: GB 134020011 19970606
0206283	C980016	Netherlands		PRODUCT NAME: LEVOFLOXACINE, DESGEWENST IN DE VORM VAN EEN SOLVAAT, IN HET BIJZONDER LEVOFLOXACINE-HEMIHYDRAAT; NAT. REGISTRATION NO/DATE: RVG 21810 - RVG 21812 19971209; FIRST REGISTRATION: GB 13402/0011 - 13402/0013 19970606
0413455	98C0040	Belgium		PRODUCT NAME: ALATROFLOXACIN; NAT. REGISTRATION NO/DATE: EU/1/98/060/001 19980327; FIRST REGISTRATION: CH 54484 19980327

Market Dynamics and Financial Trajectory for FLOXIN OTIC

Last updated: February 11, 2026

Overview

FLOXIN OTIC, the topical formulation of ofloxacin, an fluoroquinolone antibiotic, targets bacterial ear infections. It is marketed primarily by Alcon Laboratories, a Novartis division. Its global availability, clinical efficacy, and patent status influence its market performance. The following analysis examines the drug’s market environment, sales trends, competitive landscape, patent considerations, and financial outlook.

Market Overview

• Therapeutic Indication: Bacterial otitis externa, otitis media with water exposure, and other external ear infections. Off-label use includes treatment of tympanic membrane perforations.
• Market Size: The global otic antibiotic market was valued at approximately $1.2 billion in 2022, with expected compound annual growth rate (CAGR) around 4.5% through 2030 (Source: ResearchAndMarkets[1]).
• Key Regions: North America accounts for roughly 50% of sales, driven by high diagnosis rates and reimbursement frameworks. Europe and Asia-Pacific follow, with emerging markets showing increasing adoption due to rising ear infection prevalence.

Product Position and Competitive Landscape

• Market Position: FLOXIN OTIC holds a significant share in the US, its primary market; it benefits from established prescribing patterns and brand recognition.
• Main Competitors:
  • Ciprodex (ciprofloxacin/dexamethasone): Combines antibiotic and anti-inflammatory properties.
  • Vosol (0.25% acetic acid): Alternative, less expensive solution.
  • Other generic fluoroquinolones.

FLOXIN OTIC’s advantages include proven efficacy and fewer restrictions on use compared to combination therapies. Price competition from generics influences market penetration, especially outside North America.

Patent and Regulatory Status

• Patent Landscape:
  • Original patents expired in the US around 2012.
  • Supplementary patents, including formulation patents, extended exclusivity until approximately 2020.
  • The expiration of primary patents led to increased generic competition, affecting sales volume and pricing.
• Regulatory Approvals:
  • Approved by FDA in 1992.
  • Approved in multiple countries; approval processes adapted per jurisdiction, influencing market entry timing.

Sales Trends and Financial Data

• Historical Sales:

  • Peak US sales in 2011 exceeded $100 million annually.
  • Post-patent expiration, US sales declined to roughly $50 million in 2018[2].
  • Global sales have remained relatively stable at about $80 million per year, driven by international markets.

• Recent Performance:

  • 2022 sales estimated at $75 million globally.
  • Growth is stagnant or declining in mature markets due to generic competition.
  • Emerging markets show increased adoption rates, partly offsetting declines elsewhere.

• Pricing Dynamics:

  • US list prices range between $150-$200 per course.
  • Generic versions are priced approximately 30-50% lower.

• Financial Trajectory:

  • Short-term decline expected owing to patent expiry and generic provider entry.
  • Long-term prospects depend on formulation improvements, new indications, and market penetration in developing regions.
  • Potential revenue stabilization or modest growth if new formulations or combination therapies are introduced.

Market Challenges

• Generic Competition: Dominates in mature markets, exerting downward pressure on prices and margins.
• Reimbursement and Formularies: Insurance coverage restricts patient access, influencing sales volume.
• Regulatory Hurdles: Changing approval standards for new indications or formulations may delay product updates.

Potential Growth Drivers

• New Indications: Expansion into other ear-related infections or pediatric markets.
• Combination Formulations: Combining ofloxacin with anti-inflammatory agents is in development, aiming to differentiate from existing generics.
• Emerging Markets: Increasing healthcare infrastructure supports higher adoption rates.

Key Takeaways

• FLOXIN OTIC's market share is declining in the US due to patent expiration and generic competition.
• Globally, sales remain stable but are sensitive to regional regulatory and economic conditions.
• Future growth hinges on innovation, new indications, and expansion into emerging markets.
• Competitive pressures necessitate strategic positioning, including potential formulation updates and marketing.

FAQs

1. What is the primary driver of FLOXIN OTIC’s revenue decline?

   • Patent expiration facilitated generic entry, increasing price competition and reducing brand sales.

2. How does FLOXIN OTIC compare to competitors like Ciprodex?

   • It is a standalone antibiotic, with less anti-inflammatory activity, but typically priced lower. Ciprodex’s combination approach offers broader symptomatic relief but at a higher price point.

3. What are the prospects for FLOXIN OTIC in emerging markets?

   • Favorable, as rising infection rates and improving healthcare access will likely increase demand, although pricing and registration hurdles remain.

4. Are there ongoing efforts to extend FLOXIN OTIC’s patent protection?

   • No recent patents filed; focus remains on formulations and new indications.

5. How vulnerable is FLOXIN OTIC to future generic competition?

   • Highly vulnerable post-patent expiration, unless innovations or new delivery methods are developed.

Sources

[1] ResearchAndMarkets. "Global Otic Antibiotic Market," 2022. [2] IMS Health. "Pharmaceutical Sales Data," 2022. [3] FDA Product Approvals. "FLOXIN OTIC label updates," 1992–2022.